Physician profile
Douglas R Farris
NPI 1073593745
$15,698.71
in general payments reported to CMS, 2019-2025
47 companies · $2,081 in 2025
The $2,081 reported for 2025 was more than what 78% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,203 · 2020: $1,736 · 2021: $2,272 · 2022: $2,412 · 2023: $2,747 · 2024: $2,247 · 2025: $2,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,903 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,902.67 |
| Education | $172.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,961.93 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $2,212.63 | 2019-2025 | |
| Genzyme Corporation | $1,466.77 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,311.08 | 2019-2025 | Nemluvio, Twyneo, Aklief |
| Regeneron Healthcare Solutions, INC. | $871.54 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $745.32 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $727.30 | 2019-2025 | Absorica Ld, Winlevi |
| Amgen INC. | $550.30 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $516.15 | 2019-2025 | |
| Lilly USA, LLC | $384.18 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $354.14 | 2022-2024 | Sotyktu |
| Incyte Corporation | $351.94 | 2021-2025 | Opzelura |
| Ucb, INC. | $302.75 | 2021-2025 | Bimzelx |
| Almirall LLC | $258.24 | 2019-2025 | Klisyri, Seysara |
| Vyne Pharmaceuticals INC. | $244.31 | 2020-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Farris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.